Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

2 clinical studies listed.

Filters:

Primary Motor Cortex

Tundra lists 2 Primary Motor Cortex clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

RECRUITING

NCT07130786

Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastases

This is a randomized trial for patients with brain metastases in the primary motor cortex who have not had seizures to receive either the prophylactic anti-seizure medication levetiracetam (also known by its trade name Keppra) or proceed with standard of care management, which does not currently include prophylactic levetiracetam. Patients who enroll to this trial will be randomized to receive prophylactic levetiracetam or not receive prophylactic levetiracetam.

Gender: All

Ages: 18 Years - Any

Updated: 2026-03-19

1 state

Seizures
Primary Motor Cortex
Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
+2
ENROLLING BY INVITATION

NCT07176091

Clinical Efficacy of Intermittent Theta Burst Transcranial Magnetic Stimulation With Different Modes on Parkinson's Disease

TMS regulates cortical excitability through electromagnetic induction, with low-frequency stimulation suppressing and high-frequency stimulation enhancing excitability. Building on theta-gamma coupling, iTBS induces broader improvements in functional brain connectivity within a shorter stimulation period, particularly by significantly reducing abnormal variability in the prefrontal and parietal regions, demonstrating superior neuromodulatory efficiency and network remodeling capacity. This study aims to compare the symptomatic effects of different iTBS protocols on Parkinson's disease, optimize stimulation parameters, and evaluate safety, while also analyzing the time-dependent trends of therapeutic efficacy through 1- and 3-month follow-ups.

Gender: All

Ages: 40 Years - 80 Years

Updated: 2026-02-13

1 state

Parkinsonism
Transcranial Magnetic Stimilation
Intermittent Theta Burst Stimulation
+3